The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Immunotherapy discussions at ASH 2017
Immunotherapy has been a primary area of focus in lymphoma research in recent years, with treatments looking to stimulate and bolster the patient’s immune system to figh cancer. In this interview, Raul Cordoba, MD, PhD, of Fundacion Jimenez Diaz University Hospital, Madrid, Spain, gives an overview of CAR T-cells and new monoclonal antibodies, two of the most relevant immunotherapies currently in development for treating lymphoma. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA.
